Spoken approach
say this aloud Free preview- This patient with type 2 diabetes and chronic kidney disease, evidenced by an eGFR of 45 and significant albuminuria, is a prime candidate for SGLT2 inhibition.
- My first step is to confirm the indication based on KDIGO guidelines, which strongly recommend an SGLT2 inhibitor for patients with an eGFR >20 and UACR >200.
- I will perform a thorough risk assessment, specifically asking about any history of diabetic ketoacidosis, recurrent genitourinary infections, or pancreatitis, which are key contraindications.
+ 7 more steps of the spoken answer for subscribers